Network pharmacology reveals that Berberine may function against Alzheimer’s disease via the AKT signaling pathway

Abstract

ObjectiveTo investigate the mechanism underlying the effects of berberine (BBR) in the treatment of Alzheimer’s disease (AD).Methods3 × Tg AD mice were treated with BBR for 3 months, then the open field test (OFT), the novel object recognition test (NOR) and the Morris water maze (MWM) test were performed to assess behavioral performance. Hematoxylin–eosin (HE) staining, Nissl staining were used to examine histopathological changes. The pharmacological and molecular properties of BBR were obtained from the TCMSP database. BBR-associated AD targets were identified using the PharmMapper (PM), the comparative toxicogenomics database (CTD), DisGeNet and the human gene database (GeneCards). Core networks and BBR targets for the treatment of AD were identified using PPI network and functional enrichment analyses. AutoDock software was used to model the interaction between BBR and potential targets. Finally, RT-qPCR, western blotting were used to validate the expression of core targets.ResultsBehavioral experiments, HE staining and Nissl staining have shown that BBR can improve memory task performance and neuronal damage in the hippocampus of AD mice. 117 BBR-associated targets for the treatment of AD were identified, and 43 genes were used for downstream functional enrichment analysis in combination with the results of protein–protein interaction (PPI) network analysis. 2,230 biological processes (BP) terms, 67 cell components (CC) terms, 243 molecular function (MF) terms and 118 KEGG terms were identified. ALB, EGFR, CASP3 and five targets in the PI3K-AKT signaling pathway including AKT1, HSP90AA1, SRC, HRAS, IGF1 were selected by PPI network analysis, validated by molecular docking analysis and RT-q PCR as core targets for further analysis. Akt1 mRNA expression levels were significantly decreased in AD mice and significantly increased after BBR treatment (p < 0.05). Besides, AKT and ERK phosphorylation decreased in the model group, and BBR significantly increased their phosphorylation levels.ConclusionAKT1, HSP90AA1, SRC, HRAS, IGF1 and ALB, EGFR, CASP3 were core targets of BBR in the treatment of AD. BBR may exert a neuroprotective effect by modulating the ERK and AKT signaling pathways.

Investigating the Potential Anti-Alzheimer’s Disease Mechanism of Marine Polyphenols: Insights from Network Pharmacology and Molecular Docking

“…The association of DK with VEGFA in AD has not been studied to date, but it is possible that VEGFA is involved, based on previous findings that the compound crosses the BBB despite its relatively high molecular weight [32]. Wei et al reported that Hsp90 encoded by HSP90AA is involved in the degradation of Aβ and tau through the proteasome system [33]. Other studies have shown that HSP90AA1 might be a key gene in the progression of inflammation, and Hsp90 inhibitors were considered to be potent inhibitors of the inflammatory response [34,35].…”

Silibinin alleviates intestinal inflammation via inhibiting JNK signaling in Drosophila

“…The corresponding targets of SIL were obtained from the PharmMapper database and screened the targets with Norm Fit >0.5 ( Wei et al, 2023 ). The targets of IBD were searched by the OMIM, TTD, DrugBank, GeneCards, and DisGeNET databases using “inflammatory bowel disease” as the keyword ( Zu et al, 2021 ).…”

Liposome-Derived Nanosystems for the Treatment of Behavioral and Neurodegenerative Diseases: The Promise of Niosomes, Transfersomes, and Ethosomes for Increased Brain Drug Bioavailability

“…It has also been proven to have neuroprotective properties in Alzheimer's disease, namely by targeting neurotrophins and cellular processes connected to cytokine production [107,[126][127][128]. On the other hand, berberine, a natural-occurring alkaloid extracted from Berberis species, which has long been used in traditional Chinese medicine, has also been demonstrated to have neuroprotective effects, namely through inhibition of the apoptosis-inducing Akt/ERK1/2 signaling pathway, c-Jun N-terminal kinase pathway, and GSK-3β and caspase-3 activity [107,[129][130][131]. Nevertheless, despite the strong suggestion of beneficial effects in the treatment of neurodegenerative diseases, both compounds have limited efficacy due to low solubility and low bioavailability.…”